Adam S. Mostafa Sells 74,773 Shares of X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Stock

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) CFO Adam S. Mostafa sold 74,773 shares of the firm’s stock in a transaction on Friday, January 24th. The shares were sold at an average price of $0.45, for a total value of $33,647.85. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

X4 Pharmaceuticals Stock Performance

X4 Pharmaceuticals stock opened at $0.48 on Wednesday. X4 Pharmaceuticals, Inc. has a fifty-two week low of $0.26 and a fifty-two week high of $1.60. The firm’s 50 day simple moving average is $0.55 and its 200-day simple moving average is $0.61. The company has a debt-to-equity ratio of 1.26, a current ratio of 4.89 and a quick ratio of 4.80. The company has a market cap of $82.17 million, a P/E ratio of -5.35 and a beta of 0.14.

Institutional Investors Weigh In On X4 Pharmaceuticals

Hedge funds have recently bought and sold shares of the business. State Street Corp grew its stake in X4 Pharmaceuticals by 6.8% during the 3rd quarter. State Street Corp now owns 2,952,895 shares of the company’s stock valued at $1,976,000 after acquiring an additional 189,105 shares in the last quarter. Ensign Peak Advisors Inc grew its position in X4 Pharmaceuticals by 4.6% during the second quarter. Ensign Peak Advisors Inc now owns 2,546,458 shares of the company’s stock valued at $1,477,000 after purchasing an additional 111,032 shares in the last quarter. Point72 Asset Management L.P. increased its stake in X4 Pharmaceuticals by 15.1% in the 3rd quarter. Point72 Asset Management L.P. now owns 625,052 shares of the company’s stock valued at $418,000 after buying an additional 81,968 shares during the period. GSA Capital Partners LLP purchased a new stake in X4 Pharmaceuticals in the 3rd quarter worth approximately $340,000. Finally, AQR Capital Management LLC boosted its stake in shares of X4 Pharmaceuticals by 1,080.3% during the 2nd quarter. AQR Capital Management LLC now owns 424,042 shares of the company’s stock valued at $246,000 after buying an additional 388,115 shares during the period. 72.03% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several analysts have weighed in on XFOR shares. Stifel Nicolaus cut their target price on X4 Pharmaceuticals from $5.00 to $4.00 and set a “buy” rating on the stock in a research note on Thursday, November 14th. HC Wainwright restated a “buy” rating and set a $1.50 price objective on shares of X4 Pharmaceuticals in a research note on Tuesday, January 14th.

About X4 Pharmaceuticals

X4 Pharmaceuticals, Inc, a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia.